ArticleFrontiers in oncology2024
Advancing EGFR mutation subtypes prediction in NSCLC by combining 3D pretrained ConvNeXt, radiomics, and clinical features.
Article in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Radiogenomic approach combining CT-based radiomics and liquid biopsy improves prognostic stratification in patients with advanced NSCLC.The journal of liquid biopsy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: The aim of this study was to develop a novel approach for predicting the expression status of Epidermal Growth Factor Receptor (EGFR) and its subtypes in patients with Non-Small Cell Lung Cancer (NSCLC) using a Three-Dimensional Convolutional Neural Network (3D-CNN) ConvNeXt, radiomics features and clinical features. Materials and methods: A total of 732 NSCLC patients with available CT imaging and EGFR expression data were included in this retrospective study. The region of interest (ROI) was manually segmented, and clinicopathological features were collected. Radiomic and deep learning features were extracted. The instances were randomly divided into training, validation, and test sets. Feature selection was performed, and XGBoost was used to create solo models and combined models to predict the presence of EGFR and subtypes mutations. The effectiveness of the models was assessed using ROC and PRC curves. Results: We established the following models: Model Conclusions: Both deep learning models and radiomic signature-based models offer reasonably accurate non-invasive predictions of EGFR status and its subtypes. Fusion models hold the potential to enhance noninvasive methods for predicting EGFR mutations and subtypes, presenting a more reliable prediction approach.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.